CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing studyManabu Funayama, Nobutaka Hattori, Ryogen Sasaki et al.|The Lancet Neurology|2015Cited by 359
Propagative α-synuclein seeds as serum biomarkers for synucleinopathiesAyami Okuzumi, Nobutaka Hattori, Taku Hatano et al.|Nature Medicine|2023Cited by 321
Molecular genetics of Parkinson’s disease: Contributions and global trendsManabu Funayama, Nobutaka Hattori, Kenya Nishioka et al.|Journal of Human Genetics|2022Cited by 185
Homozygous alpha-synuclein p.A53V in familial Parkinson's diseaseHiroyo Yoshino, Nobutaka Hattori, Makito Hirano et al.|Neurobiology of Aging|2017Cited by 145
Serum caffeine and metabolites are reliable biomarkers of early Parkinson diseaseMotoki Fujimaki, Nobutaka Hattori, Shinji Saiki et al.|Neurology|2018Cited by 103